VNRX

SEC source: 0001477932-22-004654 · form4.xml · derivative · entry 3

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,457

Underlying: Common Stock · 28,898 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,898 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 14,450 shares and 14,448 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 15,559 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,898 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 14,450 shares and 14,448 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 15,559 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004654 · form4.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,530,068

F1 · shares: On August 3, 2021, the reporting person was awarded 24,125 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,682 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 7,842 units and 7,840 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 8,443 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004653 · form4.xml · derivative · entry 2

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,953

Underlying: Common Stock · 8,420 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 12,953 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,420 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 4,211 shares and 4,209 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 4,533 shares subject to the award previously vested and remain subject to time-based vesting.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 12,953 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,420 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 4,211 shares and 4,209 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 4,533 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004653 · form4.xml · nonDerivative · entry 1

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,279

F1 · shares: On August 3, 2021, the reporting person was awarded 7,029 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 4,569 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 2,285 units and 2,284 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 2,460 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004652 · form4.xml · derivative · entry 2

Hughes Terig · CIK 0001841309 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,647

Underlying: Common Stock · 36,821 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 56,647 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 36,821 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 18,411 shares and 18,410 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 19,826 shares subject to the award previously vested and remain subject to time-based vesting.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 56,647 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 36,821 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 18,411 shares and 18,410 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 19,826 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004652 · form4.xml · nonDerivative · entry 1

Hughes Terig · CIK 0001841309 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,740

F1 · shares: On August 3, 2021, the reporting person was awarded 30,740 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 19,981 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 9,991 units and 9,990 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 10,759 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004498 · form4.xml · nonDerivative · entry 2

Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,000

SEC source: 0001477932-22-004178 · form4.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,300

SEC source: 0001477932-22-003572 · form4.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,546,615

SEC source: 0001477932-22-004498 · form4.xml · nonDerivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,000

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 50,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-22-002258 · form4.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,249

SEC source: 0001477932-22-002188 · form4.xml · derivative · entry 4

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,020

Underlying: Common Stock · 32,020 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,020 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 16,010 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,020 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 16,010 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002188 · form4.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,159,748

F1 · shares: On August 3, 2021, the reporting person was awarded 49,645 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,375 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 8,687 units and 8,688 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002189 · form4.xml · derivative · entry 2

Hughes Terig · CIK 0001841309 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,826

Underlying: Common Stock · 19,826 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 56,647 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 19,826 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 9,913 shares on each of August 3, 2022 and August 3, 2023, respectively.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 56,647 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 19,826 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 9,913 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002189 · form4.xml · nonDerivative · entry 1

Hughes Terig · CIK 0001841309 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,759

F1 · shares: On August 3, 2021, the reporting person was awarded 30,740 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 10,759 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 5,379 units and 5,380 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002187 · form4.xml · derivative · entry 3

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,559

Underlying: Common Stock · 15,559 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,559 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 7,779 shares and 7,780 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,559 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 7,779 shares and 7,780 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002187 · form4.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,514,386

F1 · shares: On August 3, 2021, the reporting person was awarded 24,125 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,443 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 4,221 units and 4,222 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002186 · form4.xml · derivative · entry 3

Futcher Edward · CIK 0001222623 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,022

Underlying: Common Stock · 3,022 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002186 · form4.xml · nonDerivative · entry 1

Futcher Edward · CIK 0001222623 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,890

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,640 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 820 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002185 · form4.xml · derivative · entry 4

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,204

Underlying: Common Stock · 13,204 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,204 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 6,602 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,204 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 6,602 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002185 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,665

F1 · shares: On August 3, 2021, the reporting person was awarded 20,473 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 7,165 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 3,582 units and 3,583 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002184 · form4.xml · derivative · entry 2

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,533

Underlying: Common Stock · 4,533 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 12,953 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 4,533 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,266 shares and 2,267 shares on each of August 3, 2022 and August 3, 2023, respectively.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 12,953 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 4,533 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,266 shares and 2,267 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002184 · form4.xml · nonDerivative · entry 1

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,710

F1 · shares: On August 3, 2021, the reporting person was awarded 7,029 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 2,460 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,230 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002183 · form4.xml · derivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,559

Underlying: Common Stock · 15,559 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,559 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 7,779 shares and 7,780 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,559 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 7,779 shares and 7,780 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002183 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,371

F1 · shares: On August 3, 2021, the reporting person was awarded 24,125 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,443 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 4,221 units and 4,222 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002182 · form4.xml · derivative · entry 3

Nguyen Kim · CIK 0001852492 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,022

Underlying: Common Stock · 3,022 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002182 · form4.xml · nonDerivative · entry 1

Nguyen Kim · CIK 0001852492 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,140

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,640 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 820 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002180 · form4.xml · derivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,340

Underlying: Common Stock · 18,340 shares

Expires 2031-08-03

F1 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 18,340 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 9,170 shares on each of August 3, 2022 and August 3, 2023, respectively.

F1 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 18,340 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 9,170 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002181 · form4.xml · derivative · entry 2

Barnes Phillip · CIK 0001790293 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,022

Underlying: Common Stock · 3,022 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002181 · form4.xml · nonDerivative · entry 1

Barnes Phillip · CIK 0001790293 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,640

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,640 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 820 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002179 · form4.xml · derivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,967

Underlying: Common Stock · 12,967 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,967 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 6,483 shares and 6,484 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,967 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 6,483 shares and 6,484 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002179 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,434

F1 · shares: On August 3, 2021, the reporting person was awarded 20,104 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 7,036 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 3,518 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002178 · form4.xml · derivative · entry 2

Brudnick Richard · CIK 0001692359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,022

Underlying: Common Stock · 3,022 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002178 · form4.xml · nonDerivative · entry 1

Brudnick Richard · CIK 0001692359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,640

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,640 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 820 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002177 · form4.xml · derivative · entry 4

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,760

Underlying: Common Stock · 1,760 shares

Expires 2031-08-03

F4 · derivative.exercise_date: On August 3, 2021, the spouse of the reporting person was granted an option to purchase 5,030 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,760 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 880 shares on each of August 3, 2022 and August 3, 2023, respectively.

F4 · balance_after: On August 3, 2021, the spouse of the reporting person was granted an option to purchase 5,030 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,760 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 880 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002177 · form4.xml · derivative · entry 3

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,668

Underlying: Common Stock · 22,668 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 64,766 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 22,668 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 11,334 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 64,766 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 22,668 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 11,334 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002177 · form4.xml · nonDerivative · entry 2

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 955

F2 · shares: On August 3, 2021, the spouse of the reporting person was awarded 2,730 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 955 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 477 units and 478 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the spouse of the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002177 · form4.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,249

F1 · shares: On August 3, 2021, the reporting person was awarded 35,145 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,300 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 6,150 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002176 · form4.xml · derivative · entry 4

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,022

Underlying: Common Stock · 3,022 shares

Expires 2031-08-03

F4 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

F4 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002176 · form4.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,536,615

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,640 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 820 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002175 · form4.xml · derivative · entry 2

Gaetan Michel · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,676

Underlying: Common Stock · 25,676 shares

Expires 2031-10-04

F2 · derivative.exercise_date: On October 4, 2021, the reporting person was granted an option to purchase 73,360 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 25,676 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 12,838 shares on each of October 4, 2022 and October 4, 2023, respectively.

F2 · balance_after: On October 4, 2021, the reporting person was granted an option to purchase 73,360 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 25,676 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 12,838 shares on each of October 4, 2022 and October 4, 2023, respectively.

SEC source: 0001477932-22-002175 · form4.xml · nonDerivative · entry 1

Gaetan Michel · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,004

F1 · shares: On October 4, 2021, the reporting person was awarded 39,809 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,933 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 6,966 units and 6,967 units on each of October 4, 2022 and October 4, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-002174 · form4.xml · derivative · entry 3

Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,698

Underlying: Common Stock · 17,698 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 50,567 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,698 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 8,849 shares on each of August 3, 2022 and August 3, 2023, respectively.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 50,567 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,698 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 8,849 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002174 · form4.xml · nonDerivative · entry 1

Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,604

F1 · shares: On August 3, 2021, the reporting person was awarded 27,440 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 9,604 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 4,802 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-21-009123 · form4.xml · derivative · entry 2

Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-04-13

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

SEC source: 0001477932-21-009123 · form4.xml · derivative · entry 1

Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2026-04-13

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

SEC source: 0001477932-21-009122 · form4.xml · derivative · entry 4

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2030-04-13

F2 · kind: The reported transactions involved an amendment of outstanding options granted to the reporting person's wife, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options granted to the reporting person's wife, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

SEC source: 0001477932-21-009122 · form4.xml · derivative · entry 3

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2026-04-13

F2 · kind: The reported transactions involved an amendment of outstanding options granted to the reporting person's wife, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options granted to the reporting person's wife, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

SEC source: 0001477932-21-009122 · form4.xml · derivative · entry 2

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-04-13

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

SEC source: 0001477932-21-009122 · form4.xml · derivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2026-04-13

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).